Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar:54:43-57.
doi: 10.1016/j.ctrv.2017.01.003. Epub 2017 Jan 17.

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck

Rosalyn A Juergens  1 , Scott V Bratman  2 , Ming-Sound Tsao  3 , Scott A Laurie  4 , M Sara Kuruvilla  5 , Albiruni R A Razak  6 , Aaron R Hansen  7
Affiliations
Review

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck

Rosalyn A Juergens et al. Cancer Treat Rev. 2017 Mar.

Abstract

The identification of common molecular aberrations that drive cancer progression has led to targeted therapies that improve treatment efficacy in many tumor types. Epidermal growth factor receptor (EGFR) inhibitors have been used to treat both lung and head and neck cancers with squamous cell histology. These tumors often show high EGFR expression and/or increased gene copy number, but low incidence of the activating kinase domain mutations common to adenocarcinomas of the lung. In this manuscript, we review clinical trial data on EGFR-inhibitors in the treatment of squamous cell carcinoma (SqCC) of the lung and head and neck (SCCHN), including both efficacy and biomarker analyses. Although some efficacy with use of EGFR inhibitors is observed, the level of benefit varies within and across tumor types, and the predictive capacity of high EGFR protein expression and/or gene amplification, if any, is limited. Due to the lack of candidate biomarkers that consistently predict response to EGFR-inhibitor therapy across treatment setting and class of agent in SqCC of the lung and SCCHN, we explore the biology, genomics and patterns of response to EGFR-inhibitors to inform identification of potential biomarkers, highlighting several key molecules that have shown promise in preclinical studies and clinical trials across multiple cancer sites.

Keywords: Biomarkers; Disease management; EGFR inhibition; Head and neck cancer; Lung cancer; Squamous histology.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources